Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged 8 Months - United States, April 2024

Published on September 26, 2024

This report describes the percentage of infants protected against respiratory syncytial virus from maternal RSV vaccination, nirsevimab, or both.

Continue reading on website
Other news

<em>Recommendations and Reports</em>: CDC Program Evaluation Framework, 2024

September 24, 2024
This report updates the previous CDC Framework for Program Evaluation in Public Health by integrating major advancements, lessons learned, and current federal agency policies and practices.

Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024

October 3, 2024
This report describes the effectiveness of the seasonal influenza vaccine in five South American countries.